Ceftobiprole

Ceftobiprole Structure
CAS No.
209467-52-7
Chemical Name:
Ceftobiprole
Synonyms
CS-734;BAL 9141;Ceftobiprole;Abscisic Acid Impurity 4;cephalosporin,Ceftobiprole,inhibit,vancomycin,penicillin,staphylococci,Bacterial,pyrrolidinone,pathogens,gram-positive,BAL-9141,VRSA,gram-negative,Inhibitor,MRSA,BAL9141,methicillin;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[(2Z)-2-(5-aMino-1,2,4-thiadiazol-3-yl)-2-(hydroxyiMino)acetyl]aMino]-8-oxo-3-[(E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]Methyl]-,(6R,7R)-
CBNumber:
CB61509106
Molecular Formula:
C20H22N8O6S2
Molecular Weight:
534.57
MOL File:
209467-52-7.mol
MSDS File:
SDS
Modify Date:
2025/4/27 15:04:49

Ceftobiprole Properties

Density 2.00±0.1 g/cm3(Predicted)
storage temp. Store at -20°C,unstable in solution, ready to use.
solubility DMSO : 5 mg/mL (9.35 mM)
form Solid
pka 2.46±0.50(Predicted)
color Light yellow to yellow

SAFETY

Risk and Safety Statements

Ceftobiprole Chemical Properties,Uses,Production

Uses

Broad spectrum antibiotic.

Antimicrobial activity

The most important property distinguishing it from older cephalosporins is activity against methicillin-resistant staphylococci, a property conferred by a high affinity for penicillinbinding protein 2′ (2a). MICs for methicillin-resistant strains are nevertheless somewhat higher than those seen with fully susceptible strains. A similar situation exists with coagulasenegative staphylococci and with Str. pneumoniae, for which strains with reduced susceptibility to penicillin are less susceptible than fully resistant strains, while remaining within therapeutically achievable levels.
Otherwise activity approximates to that of cephalosporins of group 4 . Activity against Ps. aeruginosa is modest and much reduced against ceftazidime-resistant strains.

Acquired resistance

It is hydrolyzed by extended spectrum β-lactamases of enterobacteria , which are therefore resistant. The prospects for the emergence of resistance during extensive clinical use are presently unclear, though increased resistance in Staph. aureus appears to be difficult to induce under laboratory conditions.

Pharmacokinetics

Cmax 500 mg (667 mg prodrug): c. 35 mg/L end infusion
intravenous (30-min infusion)
Plasma half-life: c. 3 h
Volume of distribution: 18.4 L
Plasma protein binding: 16%
The prodrug is rapidly hydrolyzed in plasma to release the active form together with diacetyl (2,3-butanediol) and CO2. Distribution approximates to the extracellular fluid volume in adults. There is no accumulation on repeat dosing in subjects with normal renal function.
It is chiefly excreted in urine by glomerular filtration. A urinary concentration exceeding 1 g/L is achieved within the first 2 h of a 500 mg (active drug equivalent) dose and 80–90% of active drug can be recovered within 24 h.

Clinical Use

Ceftobiprole can be used as Broad spectrum antibiotic and in complicated infections of skin and skin structures.

Side effects

Limited studies have so far revealed no unexpected side effects. Nausea, vomiting and altered taste sensation appear to be the most common.

Ceftobiprole Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 70)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
SynZeal Research Pvt Ltd +1 226-802-2078 Gujarat, India 6514 58 Inquiry
Pharmaffiliates Analytics and Synthetics P. Ltd +91-172-5066494 Haryana, India 6739 58 Inquiry
Pharma Affiliates 172-5066494 Haryana, India 6754 58 Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6257 58 Inquiry
Hebei Chuanghai Biotechnology Co,.LTD +86-13131129325 China 5868 58 Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29857 58 Inquiry
BOC Sciences +1-631-485-4226 United States 19552 58 Inquiry
CONIER CHEM AND PHARMA LIMITED +8618523575427 China 49732 58 Inquiry
Alfa Chemistry United States 24072 58 Inquiry
TargetMol Chemicals Inc. United States 38648 58 Inquiry

Related articles

Ceftobiprole 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[(2Z)-2-(5-aMino-1,2,4-thiadiazol-3-yl)-2-(hydroxyiMino)acetyl]aMino]-8-oxo-3-[(E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]Methyl]-,(6R,7R)- CS-734 BAL 9141 cephalosporin,Ceftobiprole,inhibit,vancomycin,penicillin,staphylococci,Bacterial,pyrrolidinone,pathogens,gram-positive,BAL-9141,VRSA,gram-negative,Inhibitor,MRSA,BAL9141,methicillin Abscisic Acid Impurity 4 209467-52-7